Ramezannezhad Elham
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
J Alzheimers Dis Rep. 2025 Aug 28;9:25424823251374681. doi: 10.1177/25424823251374681. eCollection 2025 Jan-Dec.
Early degeneration of the cholinergic nucleus basalis of Meynert contributes to cognitive decline in Alzheimer's disease (AD). Microstructural damage in downstream cholinergic tracts-the cingulum bundle (CGC), entorhinal cortex (EC), and uncinate fasciculus (UNC)-often precedes volumetric atrophy. While cholinesterase inhibitors (ChEIs) can preserve cortical and hippocampal volume, their influence on white-matter integrity is unclear.
To determine whether ChEIs slow microstructural decline in four cholinergic tracts (CGC, EC, UNC, posterior thalamic radiation [PTR]) in mild cognitive impairment (MCI), and whether baseline cognitive status modulates this effect.
Diffusion-tensor imaging from the Alzheimer's Disease Neuroimaging Initiative was analyzed in 46 MCI participants receiving donepezil or rivastigmine and 62 untreated MCI controls, each scanned serially over two years. Fractional anisotropy (FA) and mean diffusivity (MD) indexed tract integrity. Linear mixed-effects models tested time × medication × baseline cognition (ADAS-Cog13) interactions, adjusting for age, sex, ε4, and white-matter hyperintensity burden.
Across groups, CGC showed progressive degeneration (FA↓, MD↑; < 0.001). Significant three-way interactions emerged for MD in bilateral CGC, FA in right EC, and MD in left PTR (all < 0.01). ChEI users with milder baseline impairment (lower ADAS-Cog13) exhibited attenuated FA loss and MD increase, indicating slower microstructural decline; those with greater initial impairment derived minimal benefit. No medication effect was detected in UNC.
ChEIs confer tract-specific, stage-dependent protection of cholinergic white matter, particularly in early MCI. The findings underscore the value of initiating ChEI therapy before substantial cognitive deterioration and highlight the need for stage-tailored interventions aimed at preserving white-matter integrity in prodromal AD.
梅纳特基底核胆碱能神经元的早期退变是阿尔茨海默病(AD)认知功能下降的原因之一。下游胆碱能神经束——扣带束(CGC)、内嗅皮质(EC)和钩束(UNC)的微观结构损伤通常先于体积萎缩出现。虽然胆碱酯酶抑制剂(ChEIs)可以保留皮质和海马体积,但其对白质完整性的影响尚不清楚。
确定ChEIs是否能减缓轻度认知障碍(MCI)患者四条胆碱能神经束(CGC、EC、UNC、丘脑后辐射[PTR])的微观结构退变,以及基线认知状态是否会调节这种作用。
对阿尔茨海默病神经影像学倡议项目中的46名接受多奈哌齐或卡巴拉汀治疗的MCI参与者和62名未接受治疗的MCI对照者进行弥散张量成像分析,每位参与者在两年内进行了多次扫描。用分数各向异性(FA)和平均扩散率(MD)来衡量神经束的完整性。采用线性混合效应模型检验时间×药物×基线认知(ADAS-Cog13)的相互作用,并对年龄、性别、ε4和白质高信号负荷进行校正。
在所有组中,CGC均呈现进行性退变(FA降低,MD升高;P<0.001)。双侧CGC的MD、右侧EC的FA和左侧PTR的MD均出现显著的三因素交互作用(均P<0.01)。基线损伤较轻(ADAS-Cog13较低)的ChEIs使用者FA损失和MD增加减弱,表明微观结构退变较慢;初始损伤较重者获益甚微。在UNC中未检测到药物作用。
ChEIs对胆碱能白质具有神经束特异性、阶段依赖性保护作用,尤其是在早期MCI中。这些发现强调了在认知功能显著恶化之前开始ChEI治疗的价值,并突出了针对前驱期AD患者进行阶段特异性干预以保留白质完整性的必要性。